Show simple item record

dc.contributor.authorDimitri, P
dc.contributor.authorHabeb, AM
dc.contributor.authorGarbuz, F
dc.contributor.authorMillward, A
dc.contributor.authorWallis, S
dc.contributor.authorMoussa, K
dc.contributor.authorAkcay, T
dc.contributor.authorTaha, D
dc.contributor.authorHogue, J
dc.contributor.authorSlavotinek, A
dc.contributor.authorWales, JK
dc.contributor.authorShetty, A
dc.contributor.authorHawkes, D
dc.contributor.authorHattersley, AT
dc.contributor.authorEllard, S
dc.contributor.authorDe Franco, E
dc.date.accessioned2016-03-18T10:36:34Z
dc.date.issued2015-08-10
dc.description.abstractCONTEXT: GLIS3 (GLI-similar 3) is a member of the GLI-similar zinc finger protein family encoding for a nuclear protein with 5 C2H2-type zinc finger domains. The protein is expressed early in embryogenesis and plays a critical role as both a repressor and activator of transcription. Human GLIS3 mutations are extremely rare. OBJECTIVE: The purpose of this article was determine the phenotypic presentation of 12 patients with a variety of GLIS3 mutations. METHODS: GLIS3 gene mutations were sought by PCR amplification and sequence analysis of exons 1 to 11. Clinical information was provided by the referring clinicians and subsequently using a questionnaire circulated to gain further information. RESULTS: We report the first case of a patient with a compound heterozygous mutation in GLIS3 who did not present with congenital hypothyroidism. All patients presented with neonatal diabetes with a range of insulin sensitivities. Thyroid disease varied among patients. Hepatic and renal disease was common with liver dysfunction ranging from hepatitis to cirrhosis; cystic dysplasia was the most common renal manifestation. We describe new presenting features in patients with GLIS3 mutations, including craniosynostosis, hiatus hernia, atrial septal defect, splenic cyst, and choanal atresia and confirm further cases with sensorineural deafness and exocrine pancreatic insufficiency. CONCLUSION: We report new findings within the GLIS3 phenotype, further extending the spectrum of abnormalities associated with GLIS3 mutations and providing novel insights into the role of GLIS3 in human physiological development. All but 2 of the patients within our cohort are still alive, and we describe the first patient to live to adulthood with a GLIS3 mutation, suggesting that even patients with a severe GLIS3 phenotype may have a longer life expectancy than originally described.en_GB
dc.description.sponsorshipThis work was supported by the Wellcome Trust. A.T.H. and S.E. are Wellcome Trust Senior Investigators and A.T.H. is an National Institute for Health Research Senior Investigator. The views expressed are those of the author and do not reflect the official policy of the Department of the Army, the Department of Defense or the U.S. Government. - See more at: http://press.endocrine.org/doi/10.1210/jc.2015-1827#sthash.nuJ86hHb.dpufen_GB
dc.identifier.citationVol. 100(10), pp. E1362–E1369en_GB
dc.identifier.doi10.1210/jc.2015-1827
dc.identifier.urihttp://hdl.handle.net/10871/20750
dc.language.isoenen_GB
dc.publisherEndocrine Societyen_GB
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/26259131en_GB
dc.rightsThis article has been published under the terms of the Creative Commons Attribution License (CC-BY; http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Copyright for this article is retained by the author(s).en_GB
dc.subjectBone Diseasesen_GB
dc.subjectCongenital Hypothyroidismen_GB
dc.subjectDevelopmental Disabilitiesen_GB
dc.subjectDiabetes Mellitusen_GB
dc.subjectFemaleen_GB
dc.subjectHumansen_GB
dc.subjectInfanten_GB
dc.subjectInfant, Newbornen_GB
dc.subjectInsulin Resistanceen_GB
dc.subjectLiver Diseasesen_GB
dc.subjectMaleen_GB
dc.subjectPhenotypeen_GB
dc.subjectTranscription Factorsen_GB
dc.titleExpanding the Clinical Spectrum Associated With GLIS3 Mutationsen_GB
dc.typeArticleen_GB
dc.date.available2016-03-18T10:36:34Z
exeter.place-of-publicationUnited States
dc.descriptionThis is the author accepted manuscript. The final version is available from the Endocrine Society via the DOI in this record.en_GB
dc.identifier.journalJournal of Clinical Endocrinology and Metabolismen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record